Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Volenrelaxin?
Volenrelaxin is a protein commercialized by Eli Lilly and Co, with a leading Phase II program in Diastolic Heart Failure...
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Volenrelaxin?
Volenrelaxin is a protein commercialized by Eli Lilly and Co, with a leading Phase II program in Diastolic Heart Failure...